Does the failure of Paxlovid to enter the medical insurance list affect the new crown drug coverage National Health Insurance Bureau response

Read Time:2 Minute, 13 Second

File photo

In the afternoon of January 11, the State Council joint prevention and control mechanism held a press conference, the Ministry of Civil Affairs, Ministry of Commerce, the State Post Office of the relevant departments and comrades in charge and experts from the China Center for Disease Control and Prevention attended the conference to introduce key institutions and key places epidemic prevention and control related to the situation, and answer media questions.

At the meeting, the reporter asked, Paxlovid produced by Pfizer failed to enter the medical insurance catalog through negotiations, will it have an impact on the new crown drug coverage?

In response, Huang Xinyu, director of the Department of Medical Services Management of the National Health Insurance Board, said that the National Health Insurance Board has always attached great importance to the protection of the new crown drugs, 2021, we have developed two medical insurance policies, including the scope of payment in the catalog. With the timely follow-up of the treatment plan, the scope of the medical insurance drug catalog was adjusted.

Huang Xinyu said that the new crown therapeutic drugs have been the focus of our high attention, the 2022 medical insurance catalog negotiations inside three new crown therapeutic drugs included in the scope of negotiations, including Pfizer’s Paxlovid, Paxlovid unfortunately did not succeed. However, do not worry too much, just last week the National Health Insurance Bureau has just formulated a notice on optimizing the medical security policy for treatment costs after the new crown B class B tube, which clearly continues the existing policy of temporary payment of medical insurance for the catalog drugs within the treatment plan, the current payment until March 31 this year, during which the patients’ medication will not be affected by anything.

In addition, in the medical insurance catalog, there are more than 600 kinds of drugs for the treatment of colds and fevers, so it should be said that the insured have a wide choice of drugs. The National Health Insurance Bureau is also paying close attention to the progress of research and development of new crown treatment, it is understood that recently some new drugs for new crown treatment have been declared to the market, we believe that with the increase of new drugs on the market, the choice of clinical drugs and the level of protection of patients will be further enhanced, the National Health Insurance Bureau will pay close attention to the price level of new crown drugs, price monitoring and management, do their best to protect the cost of new crown, and make efforts to reduce the burden of patients. Efforts to reduce the burden of patients.